Design and Analysis of Wheel Rim with Magnesium Alloys (ZK60A) by Using Solidworks and Finite Element Method

A wheel rim is a highly stressed component in an automobile that is subjected to bending and torsional loads. Because of the long life and high stresses, as well as the need for weight reduction, material and manufacturing process selection is important in rim design. There are competitions among materials andmanufacturing processes, due to cost, performance, and weight. This is a direct result of industry demand for components that are lighter, to increase performance, and cheaper to produce, while at the same time maintaining fatigue strength and other functional requirements. Lighter wheels can improve handling by reducing unsprung mass , allowing suspension to follow the terrain more closely and thus improve grip, however not all alloy wheels are lighter than their steel equivalents. Reduction in overall vehicle mass can also help to reduce fuel consumption. Nowadays cars have been using steel alloy for its wheel rim. On moving with advancements the magnesium alloy can be used for the wheel rim .In this part structural analysis of wheel rim with magnesium alloy is done and compared the results with steel alloy. As magnesium alloy (ZK60A) matches the target of lighter wheel and having many benefits compared to othermetals, it can compete with exists

An Investigation on Design and Fabrication of Electromagnetic Internal Combustion Engines

This paper reports an investigation that was carried out in a magnetic engine is according to the concept appears to be a so-called "perpetual motion machine". Here you will find its images, patent, and also you will learn information from his production and testing. The Black pointer on the disk indicates the position of piston. It is evident that with the closed shutter the piston is located stably in the upper position, and shutter renders the valuable screening of magnets, fulfilling the functions described by me. Further, with the discovery of shutter piston accomplishes reciprocating motion. The stored energy of flywheel continues to move piston to the upper position. Work: the displacements of the shutter = of 0,444 the displacement of piston = 1,251

Impact of opioid-free analgesia on pain severity and patient satisfaction after discharge from surgery: multispecialty, prospective cohort study in 25 countries

Background: Balancing opioid stewardship and the need for adequate analgesia following discharge after surgery is challenging. This study aimed to compare the outcomes for patients discharged with opioid versus opioid-free analgesia after common surgical procedures.Methods: This international, multicentre, prospective cohort study collected data from patients undergoing common acute and elective general surgical, urological, gynaecological, and orthopaedic procedures. The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-reported satisfaction with pain relief during the first week following discharge. Data were collected by in-hospital chart review and patient telephone interview 1 week after discharge.Results: The study recruited 4273 patients from 144 centres in 25 countries; 1311 patients (30.7%) were prescribed opioid analgesia at discharge. Patients reported being in severe pain for 10 (i.q.r. 1-30)% of the first week after discharge and rated satisfaction with analgesia as 90 (i.q.r. 80-100) of 100. After adjustment for confounders, opioid analgesia on discharge was independently associated with increased pain severity (risk ratio 1.52, 95% c.i. 1.31 to 1.76; P < 0.001) and re-presentation to healthcare providers owing to side-effects of medication (OR 2.38, 95% c.i. 1.36 to 4.17; P = 0.004), but not with satisfaction with analgesia (beta coefficient 0.92, 95% c.i. -1.52 to 3.36; P = 0.468) compared with opioid-free analgesia. Although opioid prescribing varied greatly between high-income and low- and middle-income countries, patient-reported outcomes did not.Conclusion: Opioid analgesia prescription on surgical discharge is associated with a higher risk of re-presentation owing to side-effects of medication and increased patient-reported pain, but not with changes in patient-reported satisfaction. Opioid-free discharge analgesia should be adopted routinely

Adsorptive removal of anthracene from water by biochar derived amphiphilic carbon dots decorated with chitosan

Anthracene belongs to the polycyclic aromatic hydrocarbon (PAH) consisting of benzene rings, unusually highly stable through more π-electrons and localized π-bond in entire rings. Aqueous-phase anthracene adsorption using carbon-based materials such as biochar is ineffective. In this paper, carbon dots (CDs) derived from the acid treatment of coconut shell biochar (CDs/MCSB) decorated with chitosan (CS) are successfully synthesized and applied for anthracene removal from aqueous solutions. The h-CDs/MCSB exhibited fast adsorption of anthracene with significant sorption capacity (Qmax = 49.26 mg g−1) with 95 % removal efficiency at 60 min. The study suggested chemisorption dominated monolayer anthracene adsorption onto h-CDs/MCSB, where a significant role was played by ion-exchange. Density Functional Theory (DFT) suggested the anthracene adsorption was dominated by the electrostatic interactions and delocalized electron, induced by higher polarizability of functional groups on the surface of hybrid CDs/MCSB assisted by chitosan (h-CDs/MCSB). In addition, the aromatic structure of CDs/MCSB and high polarizability of functional groups provided the strong interactions between benzene rings of anthracene and hybrid adsorbent-assisted multiple π-bond through delocalized π-bond and polarization-induced H-bond interactions. The presence of carboxylic and sulfonic groups on the CDs/MCSB surface also contributed to the effective adsorption of anthracene was confirmed by the fluorescence spectra. The results showed that the hybrid adsorbent was an effective material for removing PAHs, usually difficult to remove from water owing to the presence of benzene rings in their structures. Further, consistency in the DFT results suggested the outstanding binding capacity with the anthracene molecules with h-CDs/MCSB

Alterations of the CIB2 calcium- and integrin-binding protein cause Usher syndrome type 1J and nonsyndromic deafness DFNB48

Sensorineural hearing loss is genetically heterogeneous. Here we report that mutations in CIB2, encoding a Ca(2+)- and integrin-binding protein, are associated with nonsyndromic deafness (DFNB48) and Usher syndrome type 1J (USH1J). There is one mutation of CIB2 that is a prevalent cause of DFNB48 deafness in Pakistan; other CIB2 mutations contribute to deafness elsewhere in the world. In rodents, CIB2 is localized in the mechanosensory stereocilia of inner ear hair cells and in retinal photoreceptor and pigmented epithelium cells. Consistent with molecular modeling predictions of Ca(2+) binding, CIB2 significantly decreased the ATP-induced Ca(2+) responses in heterologous cells, while DFNB48 mutations altered CIB2 effects on Ca(2+) responses. Furthermore, in zebrafish and Drosophila, CIB2 is essential for the function and proper development of hair cells and retinal photoreceptor cells. We show that CIB2 is a new member of the vertebrate Usher interactome

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo